Drug Type Antibody drug conjugate (ADC) |
Synonyms h14A043 ATAC, h14A043-Antibody Targeted Amanitin Conjugate, h14A043ATAC |
Action modulators, inhibitors |
Mechanism CDCP1 modulators(CUB domain containing protein 1 modulators), RNA polymerase II inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |

| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Prostatic Cancer | Preclinical | Japan | 16 Apr 2023 |






